| Autor: |
Cordani, Nicoletta, Bianchi, Tommaso, Ammoni, Luca Carlofrancesco, Cortinovis, Diego Luigi, Cazzaniga, Marina Elena, Lissoni, Andrea Alberto, Landoni, Fabio, Canova, Stefania |
| Předmět: |
|
| Zdroj: |
International Journal of Molecular Sciences; Aug2023, Vol. 24 Issue 15, p11890, 24p |
| Abstrakt: |
Epithelial ovarian cancer (EOC), a primarily high-grade serous carcinoma (HGSOC), is one of the major causes of high death-to-incidence ratios of all gynecological cancers. Cytoreductive surgery and platinum-based chemotherapy represent the main treatments for this aggressive disease. Molecular characterization of HGSOC has revealed that up to 50% of cases have a deficiency in the homologous recombination repair (HRR) system, which makes these tumors sensitive to poly ADP-ribose inhibitors (PARP-is). However, drug resistance often occurs and overcoming it represents a big challenge. A number of strategies are under investigation, with the most promising being combinations of PARP-is with antiangiogenetic agents and immune checkpoint inhibitors. Moreover, new drugs targeting different pathways, including the ATR-CHK1-WEE1, the PI3K-AKT and the RAS/RAF/MEK, are under development both in phase I and II–III clinical trials. Nevertheless, there is still a long way to go, and the next few years promise to be exciting. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
